ReShape Lifesciences Inc
As of August 14, 2025, ReShape Lifesciences Inc. was acquired by Vyome Therapeutics Inc., in a reverse merger transaction. ReShape Lifesciences Inc. provides products and services that manage and treat obesity and metabolic diseases in the United States, Australia, Europe, and internationally. The company's product portfolio includes Lap-Band System to treat obesity and invasive surgical stapling… Read more
ReShape Lifesciences Inc (RSLS) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of June 2025: -0.771x
Based on the latest financial reports, ReShape Lifesciences Inc (RSLS) has a cash flow conversion efficiency ratio of -0.771x as of June 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-4.49 Million) by net assets ($5.83 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
ReShape Lifesciences Inc - Cash Flow Conversion Efficiency Trend (2005–2024)
This chart illustrates how ReShape Lifesciences Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
ReShape Lifesciences Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of ReShape Lifesciences Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Fragbite Group AB
ST:FRAG
|
-0.211x |
|
L&P Global Berhad
KLSE:0268
|
0.032x |
|
Addentax Group Corp
NASDAQ:ATXG
|
-0.005x |
|
GMP Property SOCIMI SA
MC:YGMP
|
0.013x |
|
Braille Energy Systems Inc
V:BES
|
-0.049x |
|
Propanc Biopharma, Inc. Common Stock
PINK:PPCB
|
-0.096x |
|
Ateliers Mecaniques D’Indonesie Tbk PT
JK:AMIN
|
0.114x |
|
Braster S.A.
WAR:BRA
|
-0.048x |
Annual Cash Flow Conversion Efficiency for ReShape Lifesciences Inc (2005–2024)
The table below shows the annual cash flow conversion efficiency of ReShape Lifesciences Inc from 2005 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $-253.00K | $-4.43 Million | 17.498x | +787.44% |
| 2023-12-31 | $6.66 Million | $-16.96 Million | -2.545x | +57.45% |
| 2022-12-31 | $3.66 Million | $-21.90 Million | -5.983x | -1692.69% |
| 2021-12-31 | $46.07 Million | $-15.38 Million | -0.334x | +43.45% |
| 2020-12-31 | $14.49 Million | $-8.55 Million | -0.590x | -0.18% |
| 2019-12-31 | $24.11 Million | $-14.20 Million | -0.589x | +32.15% |
| 2018-12-31 | $31.66 Million | $-27.49 Million | -0.868x | -169.66% |
| 2017-12-31 | $76.37 Million | $-24.59 Million | -0.322x | +95.42% |
| 2016-12-31 | $2.94 Million | $-20.66 Million | -7.028x | -14.19% |
| 2015-12-31 | $3.67 Million | $-22.61 Million | -6.155x | -111.59% |
| 2014-12-31 | $6.66 Million | $-19.38 Million | -2.909x | -131.72% |
| 2013-12-31 | $14.68 Million | $-18.43 Million | -1.255x | +33.69% |
| 2012-12-31 | $11.88 Million | $-22.48 Million | -1.893x | -90.30% |
| 2011-12-31 | $20.04 Million | $-19.94 Million | -0.995x | -116.26% |
| 2010-12-31 | $29.71 Million | $-13.66 Million | -0.460x | +89.59% |
| 2009-12-31 | $5.58 Million | $-24.66 Million | -4.418x | -49.66% |
| 2008-12-31 | $11.41 Million | $-33.67 Million | -2.952x | -472.02% |
| 2007-12-31 | $45.28 Million | $-23.37 Million | -0.516x | +9.13% |
| 2006-12-31 | $28.57 Million | $-16.23 Million | -0.568x | +89.09% |
| 2005-12-31 | $1.97 Million | $-10.28 Million | -5.205x | -- |